US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Clearmind Medicine Inc (CMND)
Clearmind Medicine Inc (CMND) ニュース

CMND

Clearmind Medicine (CMND)

Clearmind Medicine Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CMND

1 2 3 4 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/12/16	22 : 37	GlobeNewswire Inc.	Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format	NASDAQ:CMND	Clearmind Medicine Inc
2024/12/10	07 : 12	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:CMND	Clearmind Medicine Inc
2024/12/07	07 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMND	Clearmind Medicine Inc
2024/11/21	06 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMND	Clearmind Medicine Inc
2024/10/11	05 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMND	Clearmind Medicine Inc
2024/10/10	21 : 07	GlobeNewswire Inc.	Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site	NASDAQ:CMND	Clearmind Medicine Inc
2024/10/01	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:CMND	Clearmind Medicine Inc
2024/09/27	05 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMND	Clearmind Medicine Inc
2024/09/25	05 : 30	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:CMND	Clearmind Medicine Inc
2024/09/17	05 : 10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMND	Clearmind Medicine Inc
2024/09/17	05 : 06	GlobeNewswire Inc.	Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy	NASDAQ:CMND	Clearmind Medicine Inc
2024/09/17	05 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMND	Clearmind Medicine Inc
2024/09/13	05 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMND	Clearmind Medicine Inc
2024/09/12	21 : 20	GlobeNewswire Inc.	Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment	NASDAQ:CMND	Clearmind Medicine Inc
2024/09/07	05 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMND	Clearmind Medicine Inc
2024/09/06	20 : 55	GlobeNewswire Inc.	Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment	NASDAQ:CMND	Clearmind Medicine Inc
2024/09/06	20 : 55	GlobeNewswire Inc.	SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment	NASDAQ:CMND	Clearmind Medicine Inc
2024/08/30	05 : 25	GlobeNewswire Inc.	Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment	NASDAQ:CMND	Clearmind Medicine Inc
2024/08/22	05 : 11	GlobeNewswire Inc.	Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment	NASDAQ:CMND	Clearmind Medicine Inc
2024/08/17	05 : 14	GlobeNewswire Inc.	Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders	NASDAQ:CMND	Clearmind Medicine Inc
2024/08/06	21 : 57	GlobeNewswire Inc.	Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug	NASDAQ:CMND	Clearmind Medicine Inc
2024/08/06	21 : 57	GlobeNewswire Inc.	SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug	NASDAQ:CMND	Clearmind Medicine Inc
2024/07/31	20 : 44	GlobeNewswire Inc.	Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research	NASDAQ:CMND	Clearmind Medicine Inc
2024/07/19	20 : 55	GlobeNewswire Inc.	Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product	NASDAQ:CMND	Clearmind Medicine Inc
2024/07/16	22 : 02	GlobeNewswire Inc.	Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism	NASDAQ:CMND	Clearmind Medicine Inc
2024/07/16	19 : 03	GlobeNewswire Inc.	SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss	NASDAQ:CMND	Clearmind Medicine Inc
2024/07/16	19 : 03	GlobeNewswire Inc.	Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss	NASDAQ:CMND	Clearmind Medicine Inc
2024/07/12	21 : 02	GlobeNewswire Inc.	Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference	NASDAQ:CMND	Clearmind Medicine Inc
2024/06/28	20 : 55	GlobeNewswire Inc.	Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment	NASDAQ:CMND	Clearmind Medicine Inc
2024/06/20	20 : 57	GlobeNewswire Inc.	Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment	NASDAQ:CMND	Clearmind Medicine Inc

Showing the most relevant articles for your search:NASDAQ:CMND

1 2 3 4 次へ >>

Deutsche Telekom (QX)

JP Morgan Chase

Invesco QQQ Trust Series 1

US Dollar vs Yen

US Dollar vs Euro

Health Care Select Sector

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約